A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer
Author:
Funder
National Cancer Center
Publisher
Korean Cancer Association
Subject
Cancer Research,Oncology
Link
http://e-crt.org/upload/pdf/crt-2015-061.pdf
Reference22 articles.
1. Phase II Study of Vinorelbine in Heavily Previously Treated Small Cell Lung Cancer
2. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer
3. Single-agent gemcitabine in patients with resistant small-cell lung cancer
4. Topotecan in Relapsed Small-Cell Lung Cancer: Can Good Things Come in Small Packages?
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Iron oxide nanoparticles induce ferroptosis via the autophagic pathway by synergistic bundling with paclitaxel;Molecular Medicine Reports;2023-09-06
2. Impact of nab-paclitaxel plus PD-1/PD-L1 inhibitor on chemorefractory relapsed small-cell lung cancer;Future Oncology;2023-04-28
3. Functionalized FcRn-targeted nanosystems for oral drug delivery: A new approach to colorectal cancer treatment;European Journal of Pharmaceutical Sciences;2022-09
4. Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy;Clinical Lung Cancer;2022-01
5. Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis;Therapeutic Advances in Medical Oncology;2022-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3